WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) Files An 8-K Regulation FD DisclosureItem 7.01
On December10, 2017, data from preclinical studies of WVE-3972-01, Wave Life Sciences Ltd.’s (the “Company”) investigational stereopure antisense oligonucleotide designed to target the pathogenic allele of the C9ORF72 gene for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), were presented at the 28th International Symposium on ALS/MND. These data were presented by Robert Brown, Jr., DPhil, MD, with whom the Company is working in collaboration to further understand neurodegenerative and neuromuscular diseases, including ALS, and characterize the pharmacology of oligonucleotides. The slides presented containing these data are furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In addition, on December11, 2017, the Company issued a press release announcing these data. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
The information in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 7.01 | Financial Statements and Exhibits. |
(d) Exhibits.
The following exhibits relating to Item 7.01 of this Current Report on Form 8-Kshall be deemed to be furnishedand not filed:
Wave Life Sciences Ltd. ExhibitEX-99.1 2 d495597dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Preclinical Data for WVE-3972-01 Supporting ALS and FTD Programs Robert Brown,…To view the full exhibit click here
About WAVE LIFE SCIENCES LTD. (NASDAQ:WVE)
WAVE Life Sciences Ltd. is a preclinical biopharmaceutical company. The Company focuses on developing its synthetic chemistry platform to develop and commercialize a pipeline of nucleic acid-based therapeutics. It develops nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in Huntington’s disease, duchenne muscular dystrophy (DMD) and inflammatory bowel disease (IBD). In Huntington’s disease, it has programs that target HTT SNP-1 and HTT SNP-2; in DMD, it targets Exon 51, and in IBD, it targets SMAD7. It has selected lead product candidates in its programs targeting HTT SNP-1 and Exon 51. It has late-stage discovery programs in epidermolysis bullosa simplex, in which it targets KRT14 SNP-1 and KRT14 SNP-2, and in DMD, in which it is focused on an additional DMD target, AcRIIb.